INVIVYD, INC. Investment Income, Interest
INVIVYD, INC. (IVVD) reported Investment Income, Interest of $48.00 thousand for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2021-11-15
- INVIVYD, INC. investment income, interest for the quarter ending 2021-09-30 was $48.00K.
- INVIVYD, INC. investment income, interest for the quarter ending 2021-06-30 was $23.00K.
- INVIVYD, INC. investment income, interest for the quarter ending 2020-09-30 was $0.00.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 4 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month |
|---|---|---|---|---|
| 2021-09-30 | $48.00K 10-Q · filed 2021-11-15 | $71.00K derived: sum of 2 quarters · filed 2021-11-15 | $80.00K 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $23.00K 10-Q · filed 2021-09-20 | $32.00K 10-Q · filed 2021-09-20 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |